Catheterization Lab Equipment in Colorado

CardioNXT, Inc. is a medical device company specializing in 3D mapping and navigation systems for treating cardiac arrhythmias, particularly chronic atrial fibrillation. Founded in 2012 and based in Westminster, Colorado, the company develops the iMap System—an electromagnetic tracking and AI-enabled mapping platform that integrates with leading catheter technologies from Boston Scientific, Medtronic, and Abbott, as well as CardioNXT's proprietary MultiLink CS Catheter. The iMap System supports next-generation pulsed field ablation (PFA) navigation with advanced features including contact detection, customized lesion tagging, and field scaling capabilities. CardioNXT enables zero-fluoroscopy 3D mapping procedures, reducing radiation exposure during cardiac electrophysiology interventions. The company has received FDA 510(k) clearance and holds seven patents in cardiac mapping and navigation technology.

CIRCA Scientific is a medical device manufacturer specializing in innovative cardiac solutions for electrophysiologists and interventional cardiologists. Founded in 2009 and headquartered in Englewood, Colorado, the company is recognized as a leader in esophageal temperature monitoring systems. CIRCA has supported over 400,000 atrial fibrillation procedures with products deployed in more than 300 U.S. hospitals and used in over 300,000 procedures worldwide. The company holds 11 patents related to cardiac anatomy and maintains FDA clearances for its products. Core offerings include the CIRCA Temperature Monitoring System™, S-CATH™ Esophageal Temperature Probe, MATRIX12 M, CrossWise™ RF Transseptal Access System, and PeriCross™ Pericardial Access Solution. These products deliver rapid and accurate temperature detection, advanced access solutions, and real-time procedural monitoring designed to reduce complications and improve patient outcomes. CIRCA's CardioCentric™ philosophy emphasizes procedural safety and clinical excellence in cardiac interventions.

Genesee BioMedical is a Denver-based cardiac surgery device manufacturer specializing in minimally invasive and open cardiac surgical instruments. The company designs and manufactures annuloplasty rings and bands for mitral and tricuspid valve repair, cardiac surgery retractors for adult, pediatric, and neonatal procedures, coronary graft markers (silicone and stainless steel), and the ART-2 Aortic Toolkit for valve replacement and repair. Products are engineered for open, port-access, and robotic-assisted cardiac procedures. The TransForm™ McCarthy Mitral Annuloplasty Ring is a flagship semi-rigid device that adapts from D to O shape for valve repair. All retractors feature curved frames designed to follow thoracic contours and low-profile options for minimally invasive access. The company positions itself as surgeon-driven, with products developed collaboratively with cardiac surgical teams. Manufacturing capabilities include precision machining and assembly of surgical-grade instruments using stainless steel and silicone materials. The firm serves adult cardiac surgery, pediatric cardiac surgery, and neonatal cardiac care markets. Regulatory pathway and FDA status not explicitly stated on site. Company is located in Denver, Colorado.

Radiaction Medical develops scatter radiation protection systems for interventional cardiology, electrophysiology, and fluoroscopy-guided procedures. The company's primary product, the Radiaction Smart Shield, is a dynamic barrier system that deploys at the C-arm fluoroscopy system rather than requiring personnel to wear lead aprons, reducing occupational radiation exposure by over 90% according to clinical testimonials. The system deploys and retracts in 2–3 seconds, maintaining workflow efficiency in high-volume interventional labs. Radiaction's technology is designed for use in cardiac catheterization laboratories, electrophysiology labs, and operating rooms where C-arm guidance is employed. The company has clinical validation from major academic medical centers including Assuta Ashdod University Medical Center, with endorsements from interventional cardiologists and electrophysiologists. The Smart Shield addresses a documented occupational health concern: cumulative scatter radiation exposure linked to increased risk of brain tumors, breast cancer, cataracts, cognitive degradation, thyroid disease, and orthopedic injury among interventional staff. Radiaction has established a medical advisory board and has been featured in peer-reviewed and clinical trade publications including Cardiac Interventions Today and TCT (Transcatheter Cardiovascular Therapeutics). The company targets hospital systems seeking to improve occupational safety compliance while maintaining procedural volume and staff retention in high-radiation environments.

Gamamed Vascular Systems Inc. is a medical device and consumables manufacturer specializing in vascular access solutions for hospitals, clinics, and healthcare centers worldwide. The company's product portfolio encompasses intravenous catheters, advanced central venous access systems, interventional cardiology devices, and wound dressing products. Gamamed's clinical expertise is applied across four primary areas: central venous access, interventional cardiology, IV therapy, and wound care. The company positions itself as a provider of high-performance vascular solutions driven by clinical insight and extensive experience. Products are designed to support critical care, interventional procedures, and standard IV access workflows. Gamamed serves the global healthcare market with an emphasis on quality consumable and device solutions for vascular procedures and therapies.

XVIVO Perfusion AB is a Sweden-headquartered leader in ex-vivo organ preservation and perfusion technologies for transplantation. The company develops and commercializes machine perfusion systems and consumables designed to extend organ preservation time, increase organ utilization, enable organ assessment, and improve transplant outcomes. Core product lines include Kidney Assist Transport™ (hypothermic pulsatile perfusion device for donor kidneys, up to 24 hours preservation), Liver Assist™ (multi-protocol perfusion platform supporting hypothermic HOPE/DHOPE, normothermic, and sub-normothermic protocols), XPS™ (comprehensive ex-vivo lung perfusion platform for assessment and preservation), and PERFADEX® Plus (standard lung preservation solution used by >90% of transplantation clinics). The company also provides full-service organ recovery services including technology, logistics, staffing, and clinical support. XVIVO serves transplantation centers, organ procurement organizations, and research institutions globally. The company is publicly traded on Nasdaq Stockholm and maintains regulatory compliance through CE marking and FDA submissions (including 510(k) pathway for novel perfusion devices). XVIVO Academy provides clinical training, webinars, and educational resources to support adoption and optimization of organ perfusion protocols.